The DOI matches its Crossref record; 119 of the 121 references it cites were found in a registry or an index; 62 of the 229 sources its claims cite were checked for support.
Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
Open accessAbstract
This review examines the effectiveness of various surgical and endoscopic bariatric interventions in improving several components of metabolic dysfunction-associated steatotic liver disease (MASLD). Roux-en-Y gastric bypass (RYGB) consistently showed substantial long-term reductions in liver fat, inflammation, and fibrosis, achieving resolution of steatosis in up to 95% of cases. Vertical sleeve gastrectomy (VSG) provided comparable hepatic benefits, significantly reducing liver fibrosis and steatosis in approximately 60% of patients. Adjustable gastric banding (AGB) demonstrated meaningful though comparatively modest hepatic improvements, with steatosis resolution in about 42% of patients. More aggressive procedures like biliopancreatic diversion with duodenal switch (BPD-DS) showed profound metabolic effects, though with increased nutritional risk. Endoscopic therapies, including intragastric balloon (IGB) and endoscopic sleeve gastroplasty (ESG), offered notable short- to medium-term hepatic improvements, significantly reducing steatosis and fibrosis markers. Newer therapies like duodenal mucosal resurfacing (DMR) and the duodenal-jejunal bypass liner showed promising preliminary results, warranting further investigation. Overall, surgical interventions remain superior for sustained liver health improvements, while endoscopic therapies present viable alternatives for patients requiring less invasive interventions.
Overview
CoChat Summary
TL;DR
This review synthesizes evidence on bariatric surgical and endoscopic interventions for MASLD/MASH, finding that surgery—especially RYGB—provides robust, durable hepatic improvements, while endoscopic therapies offer effective short-to-medium-term alternatives. RYGB achieved steatosis resolution in up to 95% of cases, VSG in about 60%, and AGB in about 42%, with endoscopic options reducing steatosis and fibrosis markers but requiring longer-term validation.
Key findings
- RYGB showed steatosis remission in 89–95% of patients, MASH severity reduction of 75–88.9%, and full MASH remission in 38%; one-year NASH resolution without fibrosis progression occurred in 56% versus 16% with lifestyle modification alone (p < 0.0001). ALT fell by 28.5% at 6 months, 45% at 1 year, and 61.3% over 3 years.
- VSG achieved NAFLD remission in 56% and steatosis remission in 56–68.4%; one cited study reported 100% MASH resolution. ALT decreased by 50% at 6 months (31.4 to 15.7 IU/L), and at 2 years VSG outperformed RYGB for ALT reduction (32.1% vs 15.4%).
- AGB produced steatosis resolution in about 42% and modest NAS improvement (35.3%); in a paired-biopsy study, NASH criteria fell from 64% preoperatively to ~11% at follow-up, and significant fibrosis (stage ≥2) dropped from 18 to 3 patients (p < 0.001).
- Endoscopic therapies showed short-to-medium-term benefits: IGB reduced NAS from 4 ± 2.25 to 2 ± 0.75 (p = 0.03) within 6 months and severe steatosis from 52% to 4% (p < 0.0001); ESG reduced NAFLD fibrosis score by 0.5 points, hepatic steatosis index by 4.85 points, and ALT by 6.32 U/L; DMR reduced ALT by 29.3% at 6 months; POSE 2.0 achieved complete steatosis resolution in 31.6% at 6 months and 52.6% at 12 months.
Methods
- Systematic search of PubMed, MEDLINE, and Google Scholar using keywords including “MASLD,” “MASH,” “NAFLD,” “NASH,” “obesity,” “bariatric surgery,” “Roux-en-Y gastric bypass,” “sleeve gastrectomy,” “endoscopic sleeve gastroplasty,” and “intragastric balloon.”
- Included randomized controlled trials, prospective and retrospective cohort studies, and meta-analyses examining liver histology, biochemical markers, liver enzymes, and non-invasive liver health assessments after intervention.
- Data on clinical outcomes, safety profiles, and procedural effectiveness were extracted and synthesized thematically by procedure type, intervention outcomes, and time frame; quality was assessed with the Newcastle–Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for randomized controlled trials.
Limitations
- Stated: evidence for endoscopic and emerging therapies remains limited, with calls for longer-term and larger-scale studies; MAS evidence is limited by small sample sizes and absence of control groups; DJBL effects on fibrosis remain inconclusive; POSE long-term efficacy needs confirmation; DMR’s long-term role requires further study.
- Stated: BPD-DS carries risks of protein–calorie malnutrition, fat-soluble vitamin deficiencies, rare acute liver failure, and possible paradoxical fibrosis progression—one series found fibrosis worsened in 40% despite reduced steatosis.
- Evident: this is a review without pooled meta-analysis, relying on heterogeneous observational studies, small trials, and variable endpoints; several included findings are drawn from single studies or incomplete follow-up.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
53 Valid · 4 Not valid · 134 Not checked · 51 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lifestyle modification, including diet and exercise, often leads to only modest and unsustained weight loss [11]”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 1. Introduction
What the sources say
- Partly supportedcites [11] Flore, G., Preti, A., Carta, M.G., Deledda, A., Fosci, M., Nardi, A.E., Loviselli, A., and Velluzzi, F. (2022). Weight Maintenance after Dietary Weight Loss: Systematic Review and Meta-Analysis on the Effectiveness of Behavioural Intensive Intervention. Nutrients, 14. sourceExperimental — accuracy not yet measured
The Introduction (page not available) reports that only 25% of patients maintain weight loss long-term after a low-calorie diet, supporting the claim that weight loss is often unsustained. It also says combining exercise with diet produces better weight-loss outcomes than diet alone. The paper does not establish that weight loss from diet-and-exercise lifestyle modification is generally modest. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The proportion meeting NASH criteria fell from 64% pre-operatively to ~11% on follow-up”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 3. Results > 3.3. Adjustable Gastric Banding (AGB)
What the sources say
- Supportedcites [45] Dixon, 2004, Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss, Hepatology source
The NASH Grade and Stage section reports 23 patients with NASH before surgery and four at follow-up. The Results section identifies 36 patients with paired biopsies, making those proportions 64% and approximately 11%. The Patients and Preoperative Assessment section confirms that the surgery was adjustable gastric banding; page numbers are unavailable in our copy. (LLM, conf=0.94)
plainstates a causen = 36- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the number of patients with significant fibrosis (stage ≥ 2) dropped from 18 to three (p < 0.001) [45].”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 3. Results > 3.3. Adjustable Gastric Banding (AGB)
What the sources say
- Supportedcites [45] Dixon, 2004, Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss, Hepatology source
Table 4 (Discussion; page unavailable) gives fibrosis scores for 36 paired biopsies. Summing scores 2–4 yields 18 patients before weight loss and three at follow-up; the table reports P < 0.001 for the change in fibrosis scores. (LLM, conf=0.94)
plainstates a causen = 36 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a landmark prospective trial, Verrastro and colleagues demonstrated that one year following RYGB surgery, resolution of non-alcoholic steatohepatitis (NASH) without progression of fibrosis occurred in 56% of patients compared to only 16% in patients managed by lifestyle modifications alone (p < 0.0001) [28].”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 3. Results > 3.1. Roux-en-Y Gastric Bypass (RYGB)
What the sources say
- Partly supportedcites [28] Verrastro, 2023, Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): A multicentre, open-label, randomised trial, Lancet sourceExperimental — accuracy not yet measured
The Results report 54 Roux-en-Y gastric bypass responders and 15 lifestyle-group responders; with 96 participants assigned to each group and missing one-year biopsies counted as non-responses in the Statistical analysis section, these correspond to 56% and 16%. The reported comparison is significant at p<0.0001. However, the comparator received lifestyle modification plus best medical care, not lifestyle modification alone. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, limited access and surgical risks have led to increased interest in endoscopic bariatric and metabolic therapies (EBMTs) such as endoscopic sleeve gastroplasty (ESG) and intragastric balloon (IGB) placement [19,20].”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [19] Sharaiha, 2017, Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients, Clin. Gastroenterol. Hepatol. source
- Partly supportedcites [20] Lee, S.Y., Lai, H., Chua, Y.J., Wang, M.X., and Lee, G.-H. (2022). Endoscopic Bariatric and Metabolic Therapies and Their Effects on Metabolic Syndrome and Non-alcoholic Fatty Liver Disease—A Systematic Review and Meta-Analysis. Front. Med., 9. sourceExperimental — accuracy not yet measured
The Introduction says surgical risks and low uptake of bariatric surgery prompted the development of EBMTs, and it identifies ESG and IGB as examples. It does not say that limited access to surgery was a reason for the increased interest; low uptake among eligible patients is not the same as limited access. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
169 more claims · 36 with their cited sources checked
Create a free account to see all 242 claims and to verify the 11 references still open.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 64
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 4. Discussion > 4.2. Fibrosis and Steatosis Improvement
“IGB reduced NAS by two points in six months, with 87% of patients achieving ≥ 3-point improvement [72,73].”
§ Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review > 3. Results > 3.5. Intragastric Balloon (IGB)
“a cohort study employing magnetic resonance elastography and liver biopsies found an 87% patient cohort experienced a median NAS reduction of three points, with 73% achieving reductions of at least two points [73].”
Citations
Cites
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Bariatric Surgery: A Systematic Review and Meta-analysis
Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K., & Schoelles, K. (2004) · JAMA · doi:10.1001/jama.292.14.1724 · Cited by 6,800
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Brauer, M., Roth, G. A., Aravkin, A. Y., Zheng, P., Abate, K. H., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasi, M. A., Abbasian, M., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00933-4 · Cited by 2,884
Biliopancreatic Diversion with a Duodenal Switch
Hess, D. S., & Hess, D. W. (1998) · Obesity Surgery · doi:10.1381/096089298765554476 · Cited by 1,040
Mason, E. E., & Ito, C. (1967) · Surgical Clinics of North America · doi:10.1016/s0039-6109(16)38384-0 · Cited by 931
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816
Eisenberg, D., Shikora, S. A., Aarts, E., Aminian, A., Angrisani, L., Cohen, R. V., de Luca, M., Faria, S. L., Goodpaster, K. P. S., Haddad, A., et al. (2023) · Obesity Surgery · doi:10.1007/s11695-022-06332-1 · Cited by 768
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727
Cited by
Relevance of lipid droplets in metabolic dysfunction-associated steatotic liver disease
Weiskirchen, R., & Lonardo, A. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2671694 · Cited by 9
Yodoshi, T., Ollberding, N. J., McNeill, M., Ley, S. L., Kirk, S., Kleiner, D. E., Arce‐Clachar, A. C., Bramlage, K., Inge, T. H., Helmrath, M. A., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70766 · Cited by 7
Herdiana, Y. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s562536 · Cited by 4
Grama, P., Ciorba, M., Popa, S., Ismaiel, A., & Bataga, S. M. (2026) · Metabolites · doi:10.3390/metabo16080536 · Cited by 1
Onoiu, A.-I., Murray, L., Gerardin, Y., Singh, G., Egger, R., González-Serrano, S., Cambra-Cortés, V., Jiménez-Franco, A., Guilarte, C., Parada, D., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8725050/v1 · Cited by 1
Metadata
- Authors
- Tasabehji, D., Saleh, S., & Mokadem, M.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Mokadem, Mohamad
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2025-06-06
- Volume
- 14
- Issue
- 12
- Pages
- 4012
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC12194630
- OpenAlex
- W4411101122
- Semantic Scholar
- bb5a3823e743358bcf141105843a5d1e6b20511e
- Cited by
- 14
- References
- 121
- Citations by year
- 2026: 11 · 2025: 3
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- US Department of Veterans Affairs (I01 BX004774-05)
- VA Merit Review Program (I01 BX004774-05)
- Department Internal Medicine at University of Iowa Carver College of Medicine (I01 BX004774-05)
- University of Iowa Fraternal Order of Eagles Diabetes Research Center (I01 BX004774-05)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
- Keywords
- non-alcoholic fatty liver disease, bariatric surgery, endoscopic treatment, Roux-en-Y gastric bypass, sleeve gastrectomy, gastric banding, biliopancreatic diversion with duodenal switch, intragastric balloon, endoscopic sleeve gastroplasty, duodenal mucosal resurfacing, duodenal-jejunal bypass liner, hepatic steatosis, liver fibrosis, liver inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review. https://app.cochat.ai/papers/10.3390/jcm14124012
- The paper
- Tasabehji, D., Saleh, S., & Mokadem, M. (2025). Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review. Journal of Clinical Medicine. https://doi.org/10.3390/jcm14124012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.